CELLEBRITE DI LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.72 USD | -1.20% |
|
-1.47% | +23.79% |
| 04-19 | Lake Street Starts Cellebrite DI With Buy Rating, $13 Price Target | MT |
| 04-01 | BofA Securities Adjusts Cellebrite DI Price Target to $13 From $12, Maintains Buy Rating | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,501 | 826.7 | 1,709 | 2,200 | - | - |
| Enterprise Value (EV) 1 | 1,355 | 739 | 1,520 | 1,902 | 1,774 | 1,624 |
| P/E ratio | 18.2 x | 7.39 x | -20.1 x | 67.3 x | 45.1 x | 32.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 6.1 x | 3.05 x | 5.26 x | 5.85 x | 4.94 x | 4.19 x |
| EV / Revenue | 5.5 x | 2.73 x | 4.67 x | 5.06 x | 3.98 x | 3.1 x |
| EV / EBITDA | 28.3 x | 28.5 x | 24.5 x | 25.1 x | 18.5 x | 13.5 x |
| EV / FCF | 43.8 x | 54 x | 15.7 x | 18.6 x | 13.4 x | 10.1 x |
| FCF Yield | 2.28% | 1.85% | 6.37% | 5.36% | 7.44% | 9.85% |
| Price to Book | -20.5 x | 11.4 x | 52.2 x | 22.5 x | 12.5 x | 8.13 x |
| Nbr of stocks (in thousands) | 187,169 | 189,607 | 197,368 | 205,255 | - | - |
| Reference price 2 | 8.020 | 4.360 | 8.660 | 10.72 | 10.72 | 10.72 |
| Announcement Date | 16/02/22 | 15/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 246.2 | 270.7 | 325.1 | 376.1 | 445.3 | 524.6 |
| EBITDA 1 | 47.9 | 25.91 | 61.95 | 75.85 | 95.96 | 120.1 |
| EBIT 1 | 42.87 | 19.54 | 55.28 | 69.03 | 88.27 | 113.3 |
| Operating Margin | 17.41% | 7.22% | 17% | 18.35% | 19.82% | 21.6% |
| Earnings before Tax (EBT) 1 | 82.3 | 120.8 | -75.56 | 35.79 | 56.98 | 80.46 |
| Net income 1 | 71.4 | 120.8 | -81.1 | 38.44 | 51.86 | 75.39 |
| Net margin | 28.99% | 44.63% | -24.95% | 10.22% | 11.65% | 14.37% |
| EPS 2 | 0.4400 | 0.5900 | -0.4300 | 0.1592 | 0.2376 | 0.3310 |
| Free Cash Flow 1 | 30.94 | 13.68 | 96.83 | 102 | 132 | 160 |
| FCF margin | 12.57% | 5.05% | 29.78% | 27.12% | 29.64% | 30.5% |
| FCF Conversion (EBITDA) | 64.59% | 52.81% | 156.31% | 134.48% | 137.56% | 133.24% |
| FCF Conversion (Net income) | 43.34% | 11.32% | - | 265.37% | 254.55% | 212.24% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 16/02/22 | 15/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 65.89 | 67.91 | 62.38 | 62.57 | 71.68 | 74.02 | 71.23 | 76.68 | 84.18 | 93.01 | 85.39 | 90.3 | 96.38 | 104.1 | 102.2 |
| EBITDA 1 | 15.02 | 8.874 | 4.082 | 0.657 | 5.053 | 16.11 | 7.304 | 11.12 | 20.79 | 22.73 | 13.83 | 16.83 | 20.87 | 24.1 | - |
| EBIT 1 | 13.47 | 7.751 | 2.634 | -0.936 | 3.412 | 14.43 | 5.653 | 9.395 | 19.25 | 20.98 | 12.17 | 15.41 | 19.45 | 22.66 | - |
| Operating Margin | 20.44% | 11.41% | 4.22% | -1.5% | 4.76% | 19.49% | 7.94% | 12.25% | 22.87% | 22.56% | 14.26% | 17.06% | 20.18% | 21.77% | - |
| Earnings before Tax (EBT) 1 | 14.72 | 54.12 | 54.45 | 32.87 | 24.34 | 9.102 | -38.64 | -31.43 | 6.849 | -12.34 | 5.844 | 8.487 | 12.6 | 16.67 | - |
| Net income 1 | 8.139 | 51.87 | 55.44 | 33.2 | 25.09 | 7.078 | -40.6 | -32.35 | 6.5 | -14.65 | 4.623 | 7.249 | 10.92 | 14.29 | - |
| Net margin | 12.35% | 76.38% | 88.86% | 53.05% | 35.01% | 9.56% | -57% | -42.18% | 7.72% | -15.75% | 5.41% | 8.03% | 11.33% | 13.73% | - |
| EPS 2 | 0.0500 | 0.2500 | 0.2700 | 0.1700 | 0.1300 | 0.0400 | -0.2100 | -0.1700 | 0.0300 | -0.0800 | 0.0242 | 0.0352 | 0.0554 | 0.0712 | 0.0200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/11/21 | 16/02/22 | 12/05/22 | 11/08/22 | 17/11/22 | 15/02/23 | 10/05/23 | 08/08/23 | 14/11/23 | 15/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 146 | 87.6 | 190 | 298 | 426 | 577 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 30.9 | 13.7 | 96.8 | 102 | 132 | 160 |
| ROE (net income / shareholders' equity) | 156% | - | 113% | 66.6% | 43.2% | 37.8% |
| ROA (Net income/ Total Assets) | 10.8% | 5.3% | 13% | 6.08% | 8.3% | 9.75% |
| Assets 1 | 662.1 | 2,280 | -623.1 | 632 | 624.9 | 773.4 |
| Book Value Per Share 2 | -0.3900 | 0.3800 | 0.1700 | 0.4800 | 0.8600 | 1.320 |
| Cash Flow per Share 2 | 0.2200 | 0.1100 | 0.5000 | 0.3100 | 0.5600 | 0.7400 |
| Capex 1 | 5.11 | 6.9 | 5.23 | 10.1 | 11.7 | 13.1 |
| Capex / Sales | 2.08% | 2.55% | 1.61% | 2.7% | 2.64% | 2.5% |
| Announcement Date | 16/02/22 | 15/02/23 | 15/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.72
USD
Average target price
13.64
USD
Spread / Average Target
+27.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.79% | 2.2B | |
| +8.14% | 3,022B | |
| +4.28% | 81.91B | |
| +3.40% | 76.64B | |
| -16.54% | 52.31B | |
| +35.85% | 51.96B | |
| -22.85% | 47.77B | |
| +23.11% | 43.3B | |
| +64.59% | 38.29B | |
| -14.17% | 25.1B |
- Stock Market
- Equities
- CLBT Stock
- Financials Cellebrite DI Ltd.
